Gelonghui, December 8, 丨 Shiyao Group (1093.HK) opened 3.61% higher to HK$8.89, with a total market capitalization of HK$106 billion. The company announced yesterday that the collective development of SYH2055 has been approved by the China Drug Administration for clinical research in China. This product inhibits the cleavage of virus precursor proteins by acting on the main protease of the coronavirus (mPRO/3clPro), thereby blocking the replication of the virus and acting as an anti-coronavirus. Preclinical studies have shown that the product has strong and broad-spectrum antiviral activity against current mainstream mutant strains, including Omicronba.4 and BA.5 variants. The product significantly reduced lung viral load and significantly improved lung inflammation in animal models infected with COVID-19, which is superior to the same dose of nematver. The pharmacokinetic properties of this product in vivo improved markedly compared to nematvir in rats and crab-eating monkeys. It is expected to overcome the defect that nimatvir must be used in combination with ritonavir, and expand the target group of the drug to patients that cannot be covered due to concomitant use with ritonavir. Preclinical safety evaluation data also fully proved the safety of this product.